Use of abatacept in rheumatoid arthritis.

Détails

Ressource 1Télécharger: 22581564.pdf (638.97 [Ko])
Etat: Serval
Version: Final published version
ID Serval
serval:BIB_33D246307EC1
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Use of abatacept in rheumatoid arthritis.
Périodique
Swiss medical weekly
Auteur(s)
von Kempis J., Dudler J., Hasler P., Kyburz D., Tyndall A., Zufferey P., Villiger P.M.
ISSN
1424-3997 (Electronic)
ISSN-L
0036-7672
Statut éditorial
Publié
Date de publication
11/05/2012
Peer-reviewed
Oui
Volume
142
Pages
w13581
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't ; Review
Publication Status: epublish
Résumé
Abatacept (CTLA-Ig), a modulator of T-lymphocyte activation, has been approved by the Swiss health regulatory agency Swissmedic for the treatment of active rheumatoid arthritis (RA). This article summarises the key trial findings for this biologic agent in RA in different situations such as early erosive rheumatoid arthritis (RA), biologic-naïve RA, RA before and after the use of methotrexate or TNF-inhibitors and includes safety information from these trials. Based on these data, recommendations for clinical practice in Switzerland are made by a panel of experts.

Mots-clé
Abatacept, Antirheumatic Agents/adverse effects, Antirheumatic Agents/therapeutic use, Arthritis, Rheumatoid/diagnostic imaging, Arthritis, Rheumatoid/drug therapy, Humans, Immunoconjugates/adverse effects, Immunoconjugates/therapeutic use, Methotrexate/therapeutic use, Radiography, Tumor Necrosis Factor-alpha/antagonists & inhibitors
Pubmed
Web of science
Création de la notice
10/01/2013 17:50
Dernière modification de la notice
03/03/2018 15:49
Données d'usage